Managing Alzheimer's Trials In A Diverse Global Environment

By Jennifer Dennis-Wall, Ph.D.

Patients with Alzheimer’s are not treated the same everywhere. On a global level, this is immediately evident between countries through differences in diagnostic criteria. Even on a more local level, racial and ethnic disparities persist. These and other factors result in different standards of care. Multinational or not, study sites in a clinical trial must be standardized to follow the same protocol. Disparities and issues with standardization make it difficult to run successful, generalizable Alzheimer’s trials. Continue reading to learn about common disparities and faced in the Alzheimer trial space along with possible solutions.